Search Result

Results for "

cisplatin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Akt (2) Aldose Reductase (2) Apoptosis (15) ATM/ATR (1) Autophagy (5) Bacterial (4) Bcl-2 Family (2) CDK (5) COX (2) DNA Alkylator/Crosslinker (3) DNA/RNA Synthesis (4) EGFR (1) Endogenous Metabolite (1) FAK (1) Ferroptosis (3) Glucosylceramide Synthase (GCS) (1) HDAC (2) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) HSP (1) Integrin (1) Interleukin Related (1) Keap1-Nrf2 (3) LPL Receptor (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mixed Lineage Kinase (2) Monocarboxylate Transporter (1) mTOR (1) Necroptosis (1) Neurokinin Receptor (1) NF-κB (2) PARP (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (2) Pim (1) Reactive Oxygen Species (2) RIP kinase (3) STAT (3) TNF Receptor (1)
By Research Areas:	Cancer (55) Endocrinology (1) Infection (4) Inflammation/Immunology (9) Metabolic Disease (3) Neurological Disease (5)

By Targets:

Adenosine Receptor (1)

Akt (2)

Aldose Reductase (2)

Apoptosis (15)

ATM/ATR (1)

Autophagy (5)

Bacterial (4)

Bcl-2 Family (2)

CDK (5)

COX (2)

DNA Alkylator/Crosslinker (3)

DNA/RNA Synthesis (4)

EGFR (1)

Endogenous Metabolite (1)

FAK (1)

Ferroptosis (3)

Glucosylceramide Synthase (GCS) (1)

HDAC (2)

Hexokinase (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histamine Receptor (1)

HSP (1)

Integrin (1)

Interleukin Related (1)

Keap1-Nrf2 (3)

LPL Receptor (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Mixed Lineage Kinase (2)

Monocarboxylate Transporter (1)

mTOR (1)

Necroptosis (1)

Neurokinin Receptor (1)

NF-κB (2)

PARP (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PI3K (2)

Pim (1)

Reactive Oxygen Species (2)

RIP kinase (3)

STAT (3)

TNF Receptor (1)

By Research Areas:

Cancer (55)

Endocrinology (1)

Infection (4)

Inflammation/Immunology (9)

Metabolic Disease (3)

Neurological Disease (5)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17394

*Cisplatin* Maximum Cited Publications 383 Publications Verification cis-Platinum; CDDP; cis-Diaminodichloroplatinum	DNA Alkylator/Crosslinker Ferroptosis Autophagy	Cancer
Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .

HY-N3847

Eriodictyol-7-O-glucoside Eriodictyol 7-O-β-D-glucoside	Keap1-Nrf2	Metabolic Disease
Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is a potent free radical scavenger. Eriodictyol-7-O-glucoside is also an Nrf2 activator, confers protection against Cisplatin-induced toxicity .

HY-154978

Cisplatin-resistant cells-IN-1	Others	Cancer
Cisplatin-resistant cells-IN-1 (Compound 8) has high cytotoxicity against Cisplatin (HY-17394)-resistant cells. Cisplatin-resistant cells-IN-1 reduces the metabolic activity effectively in the low nanomolar range (IC₅₀: 0.14–1.79 μM in A549/A549-R, K562/K562-R, and MCF-7/MCF-7TamR cells) .

HY-17394R

Cisplatin (Standard) cis-Platinum (Standard); CDDP (Standard); cis-Diaminodichloroplatinum (Standard)	DNA Alkylator/Crosslinker Ferroptosis Autophagy	Cancer
Cisplatin (Standard) is the analytical standard of Cisplatin. This product is intended for research and analytical applications. Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .

HY-116392B

DL-threo-PDMP hydrochloride	Glucosylceramide Synthase (GCS)	Cancer
DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .

HY-B0019C

(R)-Azasetron besylate SENS-401	Phosphatase	Cancer
(R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage .

HY-129677

ORC-13661 hydrochloride	Others	Others
ORC-13661 hydrochloride is a hair cell protector. ORC-13661 hydrochloride protects sensory hair cells from aminoglycoside and Cisplatin (HY-17394) ototoxicity. ORC-13661 hydrochloride is a reversibly mechanoelectrical transducer (MET) channel permeant blocker .

HY-13816

NU6027	CDK ATM/ATR	Cancer
NU6027 is a potent and ATP-competitive inhibitor of both CDK1 and CDK2, with K_is of 2.5 µM and 1.3 µM, respectively. NU6027 is also a potent inhibitor of ATR and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner .

HY-131553

D-α-Tocopherol Succinate 1 Publications Verification Vitamin E succinate	Apoptosis	Cancer
D-α-Tocopherol Succinate (Vitamin E succinate) is an antioxidant tocopherol and a salt form of vitamin E. D-α-Tocopherol Succinate inhibits Cisplatin (HY-17394)-induced cytotoxicity. D-α-Tocopherol Succinate can be used for the research of cancer .

HY-156368

RIPK3-IN-4	RIP kinase	Inflammation/Immunology
RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .

HY-111253

CYM-5478	LPL Receptor	Neurological Disease
CYM-5478 is a potent and highly selective S1P₂ agonist with an EC₅₀ of 119 nM in a TGFα-shedding assay. CYM-5478 protects neural-derived cell lines against Cisplatin toxicity .

HY-149508

Nrf2-IN-3	Keap1-Nrf2	Cancer
Nrf2-IN-3 (Compound R16) is a Nrf2 inhibitor. Nrf2-IN-3 binds KEAP1 mutants (G333C mKEAP1) and repairs the disrupted KEAP1/NRF2 interactions. Nrf2-IN-3 sensitizes KEAP1-mutated cancer cells to Cisplatin (HY-17394) and Gefitinib (HY-50895) by repairing the mKEAP1/NRF2 complex .

HY-142956

ROS-ERS inducer 1	Reactive Oxygen Species	Cancer
ROS-ERS inducer 1 is a type II ICD (immunogenic cell death) inducer. ROS-ERS inducer 1 is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. ROS-ERS inducer 1 successfully induces endoplasmic reticulum stress (ERS) accompanied by reactive oxygen species (ROS) generation and finally lead to the release of damage-associated molecular patterns (DAMPs) in HCC cells. ROS-ERS inducer 1 displays much higher anticancer activities than Cisplatin .

HY-139696

AKR1B10-IN-1	Aldose Reductase	Cancer
AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC₅₀ of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells .

HY-147356

ERCC1-XPF-IN-2	DNA/RNA Synthesis	Cancer
ERCC1-XPF-IN-2 is a potent ERCC1-XPF endonuclease inhibitor with an IC₅₀ value of 0.6 µM. ERCC1-XPF-IN-2 shows activity in nucleotide excision repair, cisplatin enhancement and γH2AX assays .

HY-148365

NecroIr1	Mixed Lineage Kinase RIP kinase CDK	Cancer
NecroIr1 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr1 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr1 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and Mixed Lineage Kinase (MLKL), and regulates CDK4 expression .

HY-148366

NecroIr2	Mixed Lineage Kinase RIP kinase CDK	Cancer
NecroIr2 is an iridium(III) complex, serves as necroptosis inducers in Cisplatin (HY-17394)-resistant lung cancer cells (A549R). NecroIr2 selectively accumulates in mitochondria, leading to oxidative stress and loss of mitochondrial membrane potential (MMP). NecroIr2 activates receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL), and regulates CDK4 expression .

HY-N4327

Eurycomalactone	NF-κB Apoptosis Akt Bcl-2 Family	Infection Inflammation/Immunology
Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC₅₀ value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF-κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394) .

HY-44307

84-B10	Ferroptosis	Cancer
84-B10 is a 3-phenylglutaric acid derivative. 84-B10 inhibits cisplatin (HY-17394) induced tubular ferroptosis. 84-B10 attenuates cisplatin-induced mitochondrial damage and oxidative stress. 84-B10 ameliorates cisplatin-induced acute kidney injury (AKI) .

HY-13700

Nedaplatin

1 Publications Verification

NSC 375101D
DNA/RNA Synthesis Cancer

Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.

Nedaplatin 1 Publications Verification NSC 375101D	DNA/RNA Synthesis	Cancer
Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.

HY-N2757

7-Ketositosterol	Apoptosis	Cancer
7-Ketositosterol is a phytosterol isolated from the fruits of the mulberry tree (Morus alba L.). 7-Ketositosterol can significantly inhibit Cisplatin (HY-17394)-induced apoptosis in LLC-PK1 cells and has the potential to improve Cisplatin-induced nephrotoxicity .

HY-113636

Kazinol A

Others Cancer

Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .

Kazinol A	Others	Cancer
Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .

HY-162348

Antitumor agent-145	Necroptosis	Cancer
Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing necroptosis and activating the necroptosis-related immune response .

HY-101255

ODQ 2 Publications Verification
ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells .

HY-146194

NHEJ inhibitor-1	Reactive Oxygen Species	Cancer
NHEJ inhibitor-1 (Compound C2) is a trifunctional Pt(II) complex, alleviates the non-homologous end connection (NHEJ)/homologous recombination (HR)-related double strand breaks (DSBs) repairs to evade Cisplatin-resistance in non-small cell lung cancer (NSCLC). NHEJ inhibitor-1 inhibits the damage repair proteins Ku70 and Rad51 to make tumors re-sensitive to Cisplatin。NHEJ inhibitor-1 also induces ROS generation and MMP deduction .

HY-128064

Adenosine amine congener ADAC	Adenosine Receptor	Neurological Disease Inflammation/Immunology
Adenosine amine congener (ADAC) is a selective A1 adenosine receptor agonist, can ameliorate noise- and Cisplatin-induced cochlear injury. Adenosine amine congener also has neuroprotective effects .

HY-B0303A

Diphenhydramine hydrochloride 3 Publications Verification	Histamine Receptor Endogenous Metabolite Bacterial Apoptosis	Inflammation/Immunology Endocrinology Cancer
Diphenhydramine hydrochloride is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB) .

HY-19536

LLL12
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with K_is of 2 and 5 nM against PARP-2 and PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP activity .

HY-106588

Heptaplatin SKI 2053R	DNA Alkylator/Crosslinker	Cancer
Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles .

HY-P1380A

Difopein TFA	Apoptosis	Cancer
Difopein (TFA), a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interactions. Difopein (TFA) leads to induction of apoptosis and enhances the ability of cisplatin to kill cells .

HY-117082

UTL-5g GBL-5g	TNF Receptor	Inflammation/Immunology
UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors .

HY-N10313

Dehydrobruceine B	Bcl-2 Family Keap1-Nrf2 Apoptosis	Cancer
Dehydrobruceine B, a quassinoid, can be isolated from Brucea javanica. Dehydrobruceine B shows a synergistic effect with Cisplatin (HY-17394) to induce apoptosis via mitochondrial method. Dehydrobruceine B increases apoptosis-inducing factor (AIF) and Bax expression and suppresses Keap1-Nrf2 .

HY-163323

AKR1C3-IN-12	Aldose Reductase	Cancer
AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .

HY-19543

Brusatol 20+ Cited Publications NSC 172924
Brusatol (NSC 172924) is a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells to Cisplatin and other chemotherapeutic agents. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Brusatol can be developed into an adjuvant chemotherapeutic agent . Brusatol increases cellular apoptosis .

HY-W010342

6-Aminonicotinamide 4 Publications Verification	Others	Cancer
6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP ⁺-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (K_i=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin, in killing cancer cells .

HY-120139

KMH-233	Others	Cancer
KMH-233, a potent, reversible and selective l-type amino acid transporter 1 (LAT1) inhibitor, inhibits the uptake of LAT1 substrate, l-leucin (IC₅₀=18 μM) as well as cell growth. KMH-233 significantly potentiates the efficacy of Bestatin and Cisplatin even at low concentrations (25 μM) .

HY-155474

Me4Phen	Apoptosis	Cancer
Me4Phen (compound 3) is an oxygen rhenium (V) complex that depletes mitochondrial membrane potential and upregulates intracellular reactive oxygen species (ROS), leading to endoplasmic reticulum stress-mediated necrosis of cancer cells. Me4Phen is highly lipophilic and effectively overcomes Cisplatin (HY-17394) resistance in a variety of cancer cells .

HY-122552

Chrysotobibenzyl	Integrin	Cancer
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394) .

HY-155382

Lactate transportor 1	Monocarboxylate Transporter	Others Cancer
Lactate transportor 1 (compound 1) is an active lactate transporter in living cells. Lactate transportor 1 displays the cytotoxic effect, with IC₅₀ values of 3.36, 3.27,5.58 and 7.66 μM in Hela, CAL27, MCF7 and MCF10A, respectively. Lactate transportor 1 has an additive effect with Cisplatin (HY-17394) observed in HeLa cells .

HY-16559A

Riviciclib P276-00 free base	CDK	Cancer
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .

HY-128895

KL1333 1 Publications Verification	Mitochondrial Metabolism	Metabolic Disease
KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures .

HY-162344

Ir-CA	Apoptosis Autophagy	Cancer
Ir-CA is an antitumor agent. Ir-CA can accumulate in mitochondria and induces mitochondria dysfunction. Ir-CA induces apoptosis and autophagy. Ir-CA initiates mitophagy and cell cycle arrest to kill Cisplatin (HY-17394)-resistant A549R cells. Ir-CA can effectively inhibit metastasis by inhibiting MMP-2/MMP-9 .

HY-16559

Riviciclib hydrochloride 2 Publications Verification P276-00	CDK Apoptosis	Cancer
Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC₅₀s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .

HY-139038

TDRL-X80	DNA/RNA Synthesis	Cancer
TDRL-X80 is a potent inhibitor of xeroderma pigmentosum group A (XPA) protein. TDRL-X80 inhibits XPA’s DNA binding activity. TDRL-X80 exhibits activity against single, double, and Cisplatin-damaged DNA with IC₅₀s of 18, 20, and 29 μM in fluorescence polarization (FP) analyses , and with IC₅₀s of 21, 39, and 28 in ELISA Analysis .

HY-157292

2E-3-F16	Others	Cancer
2E-3-F16 is a anticancer agent. 2E-3-F16 exhibits tumor cell selectivity between NCI-H446 cancer cells and HBE cells. 2E-3-F16 enhances the sensitivity of A549 cells to Cisplatin (HY-17394) .

HY-106982

Ezlopitant CJ-11,974	Neurokinin Receptor	Neurological Disease Metabolic Disease
Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research .

HY-16558

Butein 3 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-152100

CUR5g	Autophagy	Cancer
CUR5g is a potent autophagy inhibitor. CUR5g selectively inhibits autophagosome degradation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocks the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g improves the anticancer effect of Cisplatin (HY-17394) against A549 cells both in vitro and in vivo .

HY-121222

alpha-Bisabolol	PI3K Apoptosis	Cancer
alpha-Bisabolol, an orally active sesquiterpene alcohol, induces cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. alpha-Bisabolol exerts a protective action against Cisplatin (HY-17394)-induced nephrotoxicity by mitigating inflammation and oxidative stress through the inhibition of NFκB activation. alpha-Bisabolol exhibits anti-inflammatory, analgesic, antibiotic and anticancer activities .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks